SPARC.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 05:59):

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally...

Stats
Today's Volume	2.21M
Average Volume	935 438
Market Cap	68.85B
EPS	INR0 ( 2024-02-04 )
Next earnings date	( INR0 ) 2024-05-19
Last Dividend	INR0 ( N/A )
Next Dividend	INR0 ( N/A )
P/E	-18.72
ATR14	INR0.346 (0.16%)

Volume Correlation

Long: -0.48 (neutral)

Short: -0.60 (weak negative)

Signal:(45.819) Neutral

Sun Pharma Advanced Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sun Pharma Advanced Correlation - Currency/Commodity

-0.22
( neutral )

0.41
( neutral )

-0.45
( neutral )

0.06
( neutral )

-0.14
( neutral )

0.10
( neutral )

Sun Pharma Advanced Financials

Annual	2022
Revenue:	INR2.31B
Gross Profit:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Revenue:	INR2.31B
Gross Profit:	INR592.00M (25.65 %)
EPS:	INR-7.82

FY	2022
Revenue:	INR1.37B
Gross Profit:	INR105.52M (7.69 %)
EPS:	INR-8.24

FY	2021
Revenue:	INR2.53B
Gross Profit:	INR465.55M (18.40 %)
EPS:	INR-5.77

Financial Reports:

No articles found.

Sun Pharma Advanced

Sun Pharma Advanced Research Company Limited, a biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops new chemical and biological entities, and reformulated products with a therapeutic focus on oncology, neurodegeneration, ophthalmology, and dermatology. The company offers Elepsia, a formulation of levetiracetam that is an anti-epileptic agent to treat epilepsy disorder; and Xelpros, a latanoprost ophthalmic emulsion for the treatment of open-angle glaucoma or ocular hypertension. In addition, it is developing SDN-037, a formulation of difluprednate for the treatment of inflammation and pain associated with ocular surgery that is in phase 3 clinical trial; PDP-716 to treat glaucoma, which is in phase 3 clinical trial; phenobarbital sodium for the treatment of neonatal seizures; Vodobatinib (SCO-088) for the treatment of resistant chronic myelogenous leukemia that has completed a part A of the Phase 1 study; Vodobatinib (SCC-138), which is in phase 2 clinical trial to treat Parkinson's disease; SCD-044 for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial; and SCO-120 for the treatment of hormone receptor-positive, human epidermal receptor 2 negative, and metastatic breast cancer, which is in phase 1 clinical trial. Sun Pharma Advanced Research Company Limited has a collaboration agreement with Bioprojet SCR to develop an S1P receptor 1 agonist for autoimmune disorders; and HitGen Ltd. to identify small molecule leads for targets of interest. The company was incorporated in 2006 and is based in Mumbai, India. Sun Pharma Advanced Research Company Limited is a subsidiary of Shanghvi Finance Private Limited